Ultrasound-activated Delivery
Ultrasound-activated Delivery - Related Videos
02:51
An Ultrasound-Assisted Delivery of Antibodies in a Mouse Model
0 Views •
2025
This video demonstrates a procedure of ultrasound-assisted antibody delivery in a mouse model. Retro-orbitally injected microbubbles oscillate under ultrasound, creating a transient disruption in the blood-brain barrier, permitting labeled antibodies to enter the brain.
01:28
Focused Ultrasound-Enhanced Nanoparticle Delivery in a Mouse Model for Tumor Therapy
0 Views •
2025
Begin with an anesthetized tumor-bearing mouse and shave its head.Place it in an MRI scanner integrated with the focused ultrasound system.The initial MRI scan locates the brain tumor and nearby blood vessels.Inject a contrast agent intravenously, then administer fluorescently labeled nanoparticles coated onto gas-filled microbubbles.The contrast agent and microbubbles circulate and reach the brain.Apply focused ultrasound waves to the tumor site.The ultrasound causes the microbubbles to expand...
14:10
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
0 Views •
Cited by 15 •
2010
Insonation of microbubbles is a promising strategy for tumor ablation at reduced time-averaged acoustic powers, as well as for the targeted delivery of therapeutics. The purpose of the present study is to develop low duty cycle ultrasound pulsing strategies and nanocarriers to maximize non-thermal microvascular ablation and payload delivery to subcutaneous C6 gliomas.
07:34
Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
0 Views •
Cited by 6 •
2020
Presented here is a protocol to transiently open the blood-brain barrier (BBB) either focally or throughout a mouse brain to deliver fluorescently-labeled antibodies and activate microglia. Also presented is a method to detect the delivery of antibodies and microglia activation by histology.
08:22
Ultrasound-guided Transthoracic Intramyocardial Injection in Mice
0 Views •
Cited by 16 •
2014
Echocardiography-guided percutaneous intramyocardial injection represents an efficient, reliable, and targetable modality for the delivery of gene transfer agents or cells into the murine heart. Following the steps outlined in this protocol, the operator can quickly become competent in this versatile, minimally invasive technique.
FAQs
Acoustic cavitation can create physical effects that help move therapeutic agents at a selected site. In ultrasound-activated delivery, this mechanism is one route by which acoustic energy promotes localized release or transport. Its importance lies in linking treatment location to the applied ultrasound, supporting efforts to improve local exposure while limiting systemic exposure.
Sonoporation refers to transient changes in cell membranes produced by ultrasound. These temporary changes can increase tissue or cellular permeability, allowing drugs, genes, or other therapeutic agents to enter more readily at the targeted region. Because the effect is associated with applied acoustic energy, researchers investigate it as a way to enhance localized treatment rather than relying only on systemic distribution.
Specially designed carriers provide a controllable way to associate therapeutic agents with the treatment site. Ultrasound can disrupt microbubbles or nanoparticles, helping release their contents or enhance transport. Carrier design therefore becomes central to delivery performance: the carrier must support the intended agent and respond appropriately to the selected acoustic conditions while contributing to localized treatment.
Outcomes depend on the relationship between ultrasound parameters and carrier design. Acoustic settings influence how strongly cavitation, sonoporation, or carrier disruption occurs, while carrier properties affect release and transport. Clinical research therefore focuses on optimizing these variables together, then evaluating safety and reproducibility so that localized delivery produces consistent therapeutic outcomes across studies.
A clinical research workflow begins by selecting the therapeutic agent and, when appropriate, a carrier such as a microbubble or nanoparticle. Investigators then target a chosen site, apply defined ultrasound conditions, and assess release or enhanced transport. Subsequent evaluation considers local treatment effects, systemic exposure, safety, and whether the outcome can be reproduced reliably.
Researchers may investigate this approach when treatment precision is important or when agents must reach difficult tissues. Local acoustic activation offers a strategy for concentrating delivery at a selected site while potentially limiting exposure elsewhere. Clinical studies can therefore examine drugs, genes, and other therapeutic agents in settings where improved localization or tissue access could be valuable.
Clinical research is exploring ultrasound-activated delivery for localized administration of drugs, genes, and other therapeutic agents. The approach is particularly relevant to strategies that require controlled release, increased tissue permeability, or access to difficult tissues. Its potential value is measured not only by whether an agent reaches the target, but also by treatment precision, safety, and reproducible outcomes.